Congenital diaphragmatic hernia risk factors: Difference between revisions
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Unlike other hernias that develop to a progressive weakening in the abdominal wall, CDH occurs due to anatomical defects leading to | Unlike other [[hernias]] that develop to a progressive weakening in the abdominal wall, CDH occurs due to anatomical defects leading to postero-lateral wall weakness. The use of medications and environmental exposures such as [[allopurinol]], [[lithium]] and [[Mycophenolate|mycophenolate mofetil]] as well as [[phenmetrazine]], [[thalidomide]], [[quinine]], [[cadmium]] and [[lead]] can all contribute to the development of CDH. Genetic factors such as [[trisomy 13]], [[trisomy 18]], [[trisomy 21]] and [[turner syndrome]] have all been associated with an increased incidence of CDH. A family history such as a parent or sibling affected may contribute to increased risk of CDH development. | ||
==Risk Factors== | ==Risk Factors== | ||
| Line 11: | Line 11: | ||
Causative drugs and Environmental exposures:<ref name="pmid20301533">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume= | issue= | pages= | pmid=20301533 | doi= | pmc= | url= }}</ref> | Causative drugs and Environmental exposures:<ref name="pmid20301533">{{cite journal| author=Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW | display-authors=etal| title=GeneReviews® | journal= | year= 1993 | volume= | issue= | pages= | pmid=20301533 | doi= | pmc= | url= }}</ref> | ||
* [[Allopurinol]] | *[[Allopurinol]] | ||
* [[Lithium]] | *[[Lithium]] | ||
* [[Mycophenolate|Mycophenolate mofetil]] | *[[Mycophenolate|Mycophenolate mofetil]] | ||
* [[Phenmetrazine]] | *[[Phenmetrazine]] | ||
* [[Thalidomide]] | *[[Thalidomide]] | ||
* [[Quinine]] | *[[Quinine]] | ||
* [[cadmium]] | *[[cadmium]] | ||
* [[lead]] | *[[lead]] | ||
Genetic Factors: | Genetic Factors: | ||
Revision as of 11:12, 24 April 2022
|
Congenital diaphragmatic hernia Microchapters |
|
Differentiating Congenital diaphragmatic hernia from Other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Congenital diaphragmatic hernia risk factors On the Web |
|
American Roentgen Ray Society Images of Congenital diaphragmatic hernia risk factors |
|
Directions to Hospitals Treating Congenital diaphragmatic hernia |
|
Risk calculators and risk factors for Congenital diaphragmatic hernia risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Unlike other hernias that develop to a progressive weakening in the abdominal wall, CDH occurs due to anatomical defects leading to postero-lateral wall weakness. The use of medications and environmental exposures such as allopurinol, lithium and mycophenolate mofetil as well as phenmetrazine, thalidomide, quinine, cadmium and lead can all contribute to the development of CDH. Genetic factors such as trisomy 13, trisomy 18, trisomy 21 and turner syndrome have all been associated with an increased incidence of CDH. A family history such as a parent or sibling affected may contribute to increased risk of CDH development.
Risk Factors
Risk factors for CDH include certain drugs and genetic factors.[1] Having a parent or sibling with the condition slightly increases your risk.
Causative drugs and Environmental exposures:[2]
Genetic Factors: